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AbstrAct:
The origin of chronic inflammation preceding the development of prostate cancer 
(PCa) remains unknown. We investigated possible involvement of mycoplasma 
infection in PCa by screening prostate biopsies from two groups of Russian men 
undergoing PCa diagnosis. M. hominis was detected by standard PCR in 15% of the 
125 patients in the first group and by quantitative real-time PCR in 37.4% of the 
123 men in the second group. In both groups, stratification of patients according 
to diagnosis showed that M. hominis was present at three times higher frequency 
in patients with PCa than in those with benign prostatic hyperplasia. No M. hominis 
was detected in the prostates of 27 men without detectable prostate disease. In 
addition, PCa-positive men had higher titers of antibodies against M. hominis and 
average PSA levels were higher in M. hominis-positive men. These data, together 
with previous observations linking mycoplasma infection with cell transformation, 
genomic instability and resistance to apoptosis, suggest that M. hominis infection 
may be involved in PCa development and may, therefore, be a potential PCa 
marker and/or target for improved prevention and treatment of this disease.
IntroductIon
Prostate cancer (PCa) is the most common cancer 
and the second leading cause of cancer-related death in 
men of the Western world [1]. For a number of cancers, 
including  PCa,  chronic  inflammation  associated  with 
infections  has  been  defined  as  an  important  cancer-
promoting  condition  [2-5].  Identification  of  additional 
chronic infections associated with cancer, as well as the 
mechanisms underlying their cancer-promoting activity, 
will  be  important  for  developing  new  approaches  for 
cancer prevention, diagnosis and treatment [3]. 
Despite  indications  that  chronic  infections  are 
important etiological factors for PCa [2, 4, 5], only one 
such agent has been reported to date. Infection with the 
xenotropic retrovirus XMRV was shown to be associated 
with PCa, although only in a minor proportion of PCa 
patients  [6].  Therefore,  the  major  factors  responsible 
for  PCa-promoting  chronic  inflammation  have  yet  to 
be defined. In the current study, we tested the possible 
involvement of mycoplasmas. Mycoplasmas are parasitic 
bacteria  that  infect  vertebrates.  Mycoplasma  infection 
affects the cellular metabolism and physiology of the host 
organism [7] and is associated with diseases in humans and 
animals [7, 8]. Nevertheless, these microorganisms are 
generally regarded as normal commensals of the human 
urogenital  microflora  which  only  become  pathogenic 
under specific, relatively rare conditions [7, 8]. This is Oncotarget 2011; 2:  289 - 297 290 www.impactjournals.com/oncotarget
supported by the high frequency of chronic, asymptomatic 
infection of humans by these organisms [7]. 
The  chronic  nature  of  mycoplasma  infection 
suggests that it could generate chronic inflammation with 
pro-cancerous effects. Numerous studies have shown that 
chronic mycoplasma infection of cell cultures can result 
in genetic instability and malignant transformation [9-14]. 
Mycoplasma infection was shown to increase the in vitro 
invasiveness and in vivo metastasis of different human 
tumor cells [10, 12, 14]. Mycoplasma infection was also 
shown to act as an oncogene capable of cooperating with 
H-ras or c-myc to induce transformation of embryonic cells 
[15].  Moreover,  mycoplasma  infection  both  suppresses 
p53 activity and activates NF-κB [16], thereby mimicking 
two of the most common features of tumor cells [17, 18].
Taken together, these properties of mycoplasmas led 
us to hypothesize that mycoplasma infection of prostate 
tissue  may  be  associated  with  PCa  and  play  a  role  in 
promoting  development  of  PCa  through  generation  of 
chronic inflammation. To test this hypothesis, we screened 
prostate tissue samples from men suspected of PCa due 
to elevated PSA level for presence of mycoplasma DNA. 
Comparison  of  these  results  with  those  from  control 
“normal” prostates and stratification of the data in terms 
of patient diagnosis revealed a statistically significant 
correlation between M. hominis infection and PCa 
(p<0.0001).  These  results  suggest  that  this  infectious 
agent is involved in PCa development and may, therefore, 
Figure 1: detection of mycoplasma dnA in prostate tissue from russian Patient set 1 using standard Pcr. A. Results of 
standard PCR assay for detection of an M. hominis DNA sequence (16S rRNA gene) and a control human DNA sequence (β-actin gene). 1 – 
no DNA template; 2 – “mock” DNA extraction; 3-7 – DNA from prostate biopsies of patients suspected of PCa; 8 – positive control (human 
DNA mixed with M. hominis DNA); 9 – DNA ladder. b. Frequency of detection of three Mycoplasma species in prostate biopsies (n=250, 2 
from each of 125 patients) using standard PCR assays. The percentage of patients for which the PCR assay was positive in at least one biopsy 
sample is indicated. c. Frequency of detection of M. hominis DNA by standard PCR in prostate biopsies from patients in the indicated diagnosis 
categories and in prostate samples from negative control men (“lesion-free”).
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be a potential target for improved prevention, detection 
and/or treatment of PCa.
results And dIscussIon
detection of mycoplasma infection in prostate 
tissue from patients suspected of Pca
To  determine  whether  mycoplasma  infection  is 
associated with PCa, we screened prostate samples by PCR 
for the presence of DNA sequences of the mycoplasma 
species most frequently found in the human urogenital 
tract:  M. hominis,  M. genitalium and U. urealitycum 
. We tested 250 biopsy samples, one each from the left 
and right lobes of the prostates of 125 Russian patients 
suspected of PCa due to elevated PSA levels (Patient Set 
1). This group included diagnoses ranging from benign 
prostatic  hyperplasia  (BPH)  to  high-grade  prostatic 
intraepithelial neoplasia (HGPIN) to PCa, as determined 
by  histopathological  evaluation  of  additional  biopsy 
samples. We also evaluated 162 negative control samples 
of prostate tissue taken from men that had normal prostate 
histology and PSA levels and died from non-cancer-related 
causes (6 biopsy-sized samples from each of 27 men). 
Each PCR assay was designed to simultaneously detect 
a DNA sequence specific to the mycoplasma species of 
interest and a control human DNA sequence. Figure 1A 
shows representative results for detection of M. hominis 
Figure 2: Association of M._hominis infection with HGPIn and Pca. A. Frequency of detection of M. hominis DNA by qPCR in 
prostate biopsies from patients of Russian Patient Set 2 in the indicated diagnosis categories and in prostate samples from negative control 
men (“lesion-free”). b. Quantitation of M. hominis 16S rRNA gene copies by qPCR in M. hominis-positive prostate biopsies from patients in 
Russian Patient Set 2 with BPH (n=15 biopsies from 12 patients), HGPIN (n=28 biopsies from 17 patients) or PCa (n=25 biopsies from 17 
patients). Each point indicates the concentration of M. hominis 16S rRNA DNA in a particular biopsy sample and the horizontal lines indicate 
the average value for each diagnosis group. 
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sequences in genomic DNA prepared from human prostate 
tissue. In testing the 250 patient biopsy samples, we found 
that 21.6% of the 125 patients with suspected PCa were 
positive for one of the tested species of mycoplasma in at 
least one biopsy sample (Figure 1B). M. hominis infection 
was most prevalent (found in 15.2% of the patients), while 
M. genitalium and U. urealitycum were only detected in 
5.6% and 0.8% of the patients, respectively. Notably, none 
of the three mycoplasma species were detected in any of 
the  162  negative  control  prostate  samples  or  in  rectal 
smears taken from 105 of the 125 patients suspected of 
PCa  to  control  for  possible  contamination  of  prostate 
tissue samples with rectal flora. 
The  presence  of  M. hominis and U. urealyticum 
in  prostate  tissue  was  confirmed  by  seeding  tissue  on 
selective  nutrient  culture  media.  M. genitalium was 
not  analyzed  using  this  method  since  its  cultivation  is 
reportedly extremely difficult [19]. In testing the same 
250 biopsies that were analyzed by PCR, we found that 
the frequency of identification of U. urealitycum was the 
same with the cultivation assay as with PCR (0.8%). M. 
hominis was also detected by cultivation, although at a 
lower frequency than by PCR (6.3 % vs. 15.2%). This 
difference could be due to the exacting requirements for 
cultivation of M. hominis or detection of DNA from dead 
bacteria in the PCR assay. Despite the lower sensitivity 
of the cultivation assay, growth of mycoplasma from at 
least some patient samples confirms the presence of active 
mycoplasma infection in prostate tissue. Notably, none of 
the 162 negative control prostate samples were positive in 
the M. hominis or U. urealyticum cultivation assays.
Since  M. hominis was detected much more 
frequently  than  the  other  tested  mycoplasma  species, 
we focused specifically on this species for the remainder 
of  the  study.  As  shown  in  Figure  1C,  when  the  125 
patients  in  Patient  Set  1  were  divided  based  on  their 
histopathologically determined diagnosis, it was revealed 
that the frequency of M. hominis infection increased with 
the severity of the diagnosis (6.8%, 13.0% and 22.4% in 
BPH, HGPIN and PCa patients, respectively, as compared 
to 0% in the 27 control patients with normal “lesion-free” 
prostates). HGPIN is increasingly considered a precursor 
to PCa in many, if not most, cases. In contrast, there is 
no clear association of BPH with PCa. Our data shows 
that M. hominis was detected 3-times more frequently in 
patients with either HGPIN or PCa (20%) than in patients 
with BPH (6.8%). Looking at the data in terms of the 
occurrence of HGPIN and PCa in M. hominis-positive 
versus  M. hominis-negative  groups,  it  is  clear  that  M. 
hominis infection is associated with development of PCa. 
84.2% of subjects found to be M. hominis-positive were 
diagnosed with either HGPIN or PCa, while only 57.6% 
of  M. hominis-negative  PSA-positive  subjects  fell  into 
these diagnosis categories (p=0.033). 
Analysis of M. hominis infection in prostate tissue 
using quantitative real-time Pcr
To confirm the findings described above, we used 
a quantitative real-time PCR (qPCR) assay to detect M. 
hominis  16S  rRNA  gene  sequences  in  an  independent 
set of patient samples (Patient Set 2). We analyzed 246 
new prostate biopsy samples (one each from the right and 
left prostate lobes of 123 Russian patients suspected of 
PCa due to elevated PSA level) as well as the same 162 
“normal”  negative  control  prostate  tissue  samples  that 
we used in our initial standard PCR screen. We detected 
M. hominis DNA in at least one biopsy sample from 46 
(37.4%) of the 123 patients suspected of PCa, but not 
in any of the 27 negative control patients. When Patient 
Set 2 was divided according to diagnosis, the qPCR data 
indicated that 53% of patients with HGPIN and 54.8% of 
patients with PCa were infected with M. hominis (Figure 
2A). In contrast, none of the negative control patients and 
only 20% of patients with BPH were M. hominis-positive. 
The association of M. hominis infection with HGPIN and 
PCa was highly statistically significant when compared to 
either normal “lesion-free” controls (p=0.0001) or BPH 
patients (p=0.002). Analysis of the qPCR data in terms 
of  the  occurrence  of  HGPIN  and  PCa  in  M. hominis-
positive  versus  –negative  groups  showed  that  74%  of 
M. hominis-positive patients had HGPIN or PCa, while 
only 38% of M. hominis-negative patients were in these 
diagnosis groups (p<0.002). Thus, M. hominis infection 
was associated with a 2-fold higher risk of PCa in this 
patient population. 
The greater frequency of M. hominis detection by 
qPCR in Russian Patient Set 2 as compared to standard PCR 
in Russian Patient Set 1 (for example, 54.8% versus 22.4 
% for PCa samples) is likely due to the greater sensitivity 
of  the  qPCR  technology  rather  than  differences  in  the 
presence of mycoplasma in the two patient populations. 
This is supported by our finding of a ~3:1 ratio of M. 
hominis  presence  in  HGPIN+PCa  patients  versus  BPH 
patients in both the standard and qPCR studies. 
In addition to finding that the rate of M. hominis 
infection  is  greater  in  PCa  and  HGPIN  patients  than 
in  BPH  or  “normal”  patients,  we  identified  a  similar 
correlation for the degree of M. hominis infection. Using 
our qPCR assay we found that the mean concentration 
of M. hominis DNA in samples from BPH patients was 
less  than  4x104  copies/ml  (Figure  2B).  In  comparison, 
the mean concentration of M. hominis DNA in HGPIN 
samples was more than 10-fold higher (5.5x105 copies/ml) 
and PCa samples showed an even higher level of infection 
(9.1x105  copies/ml).  This  positive  correlation  between 
the quantity of M. hominis in the prostate and diagnoses 
of  HGPIN  or  PCa  provides  additional  support  for  the 
association between M. hominis and PCa and is consistent 
with the possibility that M. hominis infection plays a role 
in development of PCa.Oncotarget 2011; 2:  289 - 297 293 www.impactjournals.com/oncotarget
detection of anti-M. hominis antibodies in the 
serum of patients suspected of Pca
As an independent means to confirm mycoplasma 
infection of patient prostate tissue, we tested serum from 
118 men by ELISA for the presence of IgG antibodies 
against recombinant M. hominis protein p120. The negative 
control patients were not analyzed by ELISA since their 
serum was not available. As shown in Figure 3, 35% and 
44.8  %  of  PCa  and  HGPIN  patients  were  positive  for 
anti-M. hominis IgG, respectively. In contrast, only 19% 
of patients with BPH were positive. The correlation of 
positive M. hominis-specific ELISA results with HGPIN/
PCa  as  compared  to  BPH  was  statistically  significant 
(р=0.042)  For  75%  of  the  patients  analyzed  by  both 
ELISA and real-time PCR, the two assays gave consistent 
results (M. hominis-positive or -negative). The two assays 
gave disparate results in the other 25% of cases, perhaps 
due  to  the  different  biological  materials  analyzed  and/
or the different natures and sensitivities of the methods. 
Thus, while the ELISA assay provided confirmation of the 
association between M. hominis infection and diagnoses 
of  HGPIN  and  PCa,  qPCR  was  found  to  be  the  most 
sensitive method of M. hominis detection. Nevertheless, 
if the association between M. hominis and PCa is borne 
out, the humoral immune response to M. hominis could 
provide a clinically useful diagnostic marker reflective of 
disease development and stage. 
Preferential localization of Mycoplasma infection 
in the left lobe of the prostate
Since we had biopsy samples from each of the two 
lobes of the prostate from patients suspected of PCa, we 
used our data from Patient Set 2 to determine whether 
mycoplasma infection showed any bias in localization. 
As  illustrated  in  Figure  4,  for  those  patients  in  which 
M. hominis was detected, it was found in both lobes of 
Figure 3: elIsA-based detection of anti-M._hominis IgG in the serum of patients suspected of Pca. ELISA was performed 
for 118 patients out of the 123 patients in Russian Patient Set 2 for which serum was available. The percentage of patients in BPH (n=52), 
HGPIN (n=29) and PCa (n=37) diagnosis categories that were positive by ELISA is shown. 
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Figure 4: the proportion of M._hominis-positive patients in which both prostate lobes were positive (r&l) or only the 
left (l) or right (r) lobe was positive. Data is from qPCR analysis of Russian Patient Set 2 and is shown for M. hominis-positive patients 
of all diagnosis groups (“total”, left column, n=46) or the HGPIN+PCa groups only (right column, n=34).
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the prostate in 46% of cases, only in the right lobe in 
11% of cases, and only in the left lobe in 43% of cases. 
Thus, when only one lobe of the prostate was infected, 
the infection occurred in the left lobe 4 times more often 
than in the right lobe (р=0.04). A  similar  pattern  was 
observed when only patients diagnosed with HGPIN or 
PCa were analyzed, although this did not reach statistical 
significance.  In  this  case,  infection  of  both  lobes  was 
found  in  53%  of  M. hominis-positive  patients,  while 
infection of only the right or left lobe was seen in 12% 
and 35% of patients, respectively. The observed bias in 
infection localization might be due to the anatomy of the 
prostate, particularly in terms of blood flow through the 
tissue. This possibility is supported by a study of 300 
patients with chronic prostatitis in which inflammatory 
changes were detected in both prostate lobes in 42% of 
cases, only in the right lobe in 13.3% of cases, and only 
in the left lobe in 44.7% of cases [20, 21]. In this study, it 
was postulated that anatomic features resulting in venous 
stagnation of blood contributed to prostate tissue damage 
and its preference for the left lobe. In addition, clinicians 
have noted that inflammatory changes are more expressed 
and deep in the left lobe of the prostate than the right, even 
if both lobes are affected [20, 21]. Such tissue changes 
appear to promote penetration of pathogenic organisms 
into  the  prostate  tissue.  For  example,  in  patients  with 
chlamydia prostatitis, pathological changes are both more 
common and more severe in the left prostate lobe than the 
right [20]. 
relationship between PsA level and M. hominis 
infection
Prostate specific antigen (PSA) is a protein produced 
by the prostate gland that is normally present in the blood 
at very low levels. Elevation of the serum PSA level is 
associated  with  PCa  and  other  prostate  disorders  [22]. 
Measurement  of  serum  PSA  level  is  widely  used  as 
a screening tool for early detection of PCa, although it 
frequently provides false positive results [22]. To further 
explore the association between M. hominis infection and 
PCa, we investigated whether a correlation existed between 
presence of M. hominis and serum PSA level. Serum PSA 
levels were determined for the 125 patients in Patient Set 
1 at the time that biopsies were taken. Separation of these 
patients  into  M. hominis-positive  and  -negative  groups 
revealed  a  positive  correlation  between  PSA  level  and 
M. hominis infection (Figure 5). The average PSA level 
in M. hominis-positive patients was 21 ng/ml, while the 
average level in M. hominis-negative patients was 12 ng/
ml. This difference was statistically significant (p=0.024) 
and provides further support for association of M. hominis 
infection with development of PCa.
detection of M. hominis in the prostate tissue of 
American men suspected of Pca
To  extend  our  findings  beyond  Russian  patient 
populations,  we  performed  a  small  pilot  study  to 
investigate the presence of M. hominis in American men 
suspected of PCa. Prostate biopsies (n=116, 2 from each 
of 58 Cleveland Clinic patients) were screened using the 
M. hominis 16S rRNA qPCR assay. While the number 
of analyzed biopsies was too small to make statistically 
reliable conclusions regarding the correlation between 
mycoplasma  infection  and  diagnosis,  we  did  find  that 
a  substantial  proportion  of  the  samples  (15.5%)  were 
M. hominis-positive  (Table  1).  These  preliminary  data 
demonstrate that infection of the prostate by this species 
of  mycoplasma  is  not  an  endemic  characteristic  of 
Russian men and, therefore, may have general importance 
Histopathology 
evaluation
Number of 
patients
M.hominis
positive (number)
M.hominis
positive (%)
PCa positive 27 5 18.5
PCa negative 31 4 12.9
Total 58 9 15.5
table 1: occurrence of M._hominis-positive samples 
among prostate biopsies of American patients.
Figure 5: serum PsA levels in patients suspected of Pca 
(russian Patient set 1) that were found to be M._hominis-
negative (n=99) or –positive (n=26) by standard Pcr. Each 
point represents an individual patient and the horizontal line indicates 
the mean within each group.
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in consideration of potential strategies for prevention and 
treatment of PCa. 
conclusIons 
Despite  considerable  well-justified  speculation 
that mycoplasma infection might play a role in cancer 
promotion,  the  current  study  provides,  to  our  best 
knowledge,  the  first  demonstration  of  a  statistically 
significant  association  between  mycoplasma  infection 
and cancer development. Our results are notable in that M. 
hominis infection was detected by qPCR in a substantial 
fraction of men diagnosed with HGPIN or PCa (>50%), 
yet only 20% of men with BPH and 0% of men with 
apparently normal prostates. These differences were highly 
statistically significant, but will need to be confirmed in 
additional large-scale epidemiological studies involving 
men of different nationalities. If it is borne out that M. 
hominis  infection  is  a  predisposing  factor  in  PCa,  M. 
hominis  will  become  a  promising  new  target  for  PCa 
diagnosis, prevention and treatment. In particular, if M. 
hominis is found to play a causative role in PCa, early 
detection and eradication of M. hominis infection could 
become  a  routine  PCa-preventive  approach.  However, 
even if M. hominis infection is only “passively” associated 
with PCa, it could be used as an additional diagnostic 
marker to improve the accuracy of PSA-based diagnoses. 
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MAterIAls And MetHods
Prostate tissue samples
For  Russian Patient Sets 1 and 2,  prostate  tissue 
samples  were  obtained  in  the  urological  clinic  of  the 
Setcheinov  Moscow  Medical  Academy  from  125  (Set 
1)  and  123  (Set  2)  patients  suspected  of  PCa  due  to 
elevated  PSA  level.  Patient  age  ranged  from  45  to  83 
years (mean = 65.5±1.02 years). Transrectal polyfocal 
prostate  biopsies  were  performed  under  ultrasonic 
pointing using sterile biopsy needles. For each patient, 
twelve main columns of prostate tissue were taken for 
morphological and histological studies and two additional 
samples  (one  each  from  the  peripheral  left  and  right 
prostate lobes) were taken for our research. Thus, 496 
acerate biopsy samples of prostate tissue were obtained. 
In  addition,  rectal  smears  were  taken  from  105  of  the 
patients in Set 1 for use as controls. Negative controls 
(n=27) were Russian men (age 33-60, mean = 55.2±2.5 
years) that had normal PSA levels and prostate histology 
and died from causes unrelated to cancer. For each control 
prostate, 6 tissue samples of biopsy size were taken from 
the same zones biopsied in patients (162 total samples). 
For both patients and controls, to reduce the possibility of 
degradation of mycoplasmal DNA within the tissue, DNA 
was prepared from prostate tissue either immediately upon 
collection or after no more than 1-2 days of storage at -70 
degrees.  American Patient Set:  Prostate  tissue  samples 
were obtained at the Urological Institute of the Cleveland 
Clinic from 58 patients suspected of PCa due to elevated 
PSA  level.  Transrectal  polyfocal  prostate  biopsies 
were performed under ultrasonic pointing. Two tissue 
samples were taken from each patient (one each from the 
peripheral left and right prostate lobes). Histopathological 
studies leading to diagnosis and all PCR and qPCR studies 
were performed in a double-blinded manner.
dnA extraction
DNA  was  prepared  from  tissue  samples  using 
Proteinase K treatment (1 µg/ml final concentration of 
Proteinase K, incubated at 650C for 1.5-2 hours) followed 
by  DNA  extraction  using  the  DNA-sorb-В  reagent  set 
(InterLabService,  Moscow,  Russia)  according  to  the 
manufacturer’s instructions. The obtained purified DNA 
was stored at -200С. 
standard Pcr assays for detection of mycoplasma 
dnA in Patient set 1 samples
PCR  assays  were  designed  to  simultaneously 
detect specific DNA sequences of either M. hominis, M. 
genitalium, or U. urealyticum along with a human DNA 
sequence  (as  an  internal  control  for  DNA  quality  and 
quantity). Primer sequences are available upon request. 
Plasmid DNAs containing M. hominis, M. genitalium or 
U. Urealitycum sequences were used as positive controls. 
”Hot  start”  PCR  was  performed  using  TC-Taq-DNA-
polymerase.  Amplification  conditions  were:  1  cycle 
at 95°С – 10 min; 45 cycles at 94°С – 10 sec, 61-63°С 
(depending on mycoplasma species) –10 sec, 72°С – 10 
sec.  Reaction  products  were  electrophoresed  in  1.5% 
agarose gels containing 1 µg/ml ethidium bromide.
Quantitative real-time Pcr (qPcr) assay for 
detection of M. hominis 16s rrnA sequences in 
Patient set 2 samples
We designed a qPCR assay for quantitative detection 
of M. hominis 16S rRNA sequences. The specific primers 
and “TaqMan” probe for the M. hominis 16S rRNA qPCR 
assay were designed in accordance with the rules provided 
by Primer Express (Applied Biosystems): forward primer: 
5’-aaa-aga-tga-ggg-tgc-gga-aca-3’; reverse primer: 5’-ttc-Oncotarget 2011; 2:  289 - 297 296 www.impactjournals.com/oncotarget
cct-act-gct-gcc-tcc-cgt–3’; probe: 5’ - FAM- tgg-ccg-ttc-
agt-ctc-tcg-acc-cgg-cta BTQ1– 3’. The probe was marked 
on the 5’-end with the fluorescent reporter FAM and on the 
3’-end with the quencher BTQ1. Amplification conditions 
were: 1 cycle at 950С – 300 sec; 50 cycles at 600С – 50 sec, 
950С – 20 sec. Analysis was carried out using the ANK-32 
tool (IAnP RAS Institute for Analytical Instrumentation 
Russian Academy of Science and Bauman Moscow State 
Technical University, Russia). 
Mycoplasma cultivation assays
 Presence of M. hominis and U. urealyticum in 
prostate tissue samples was determined by seeding tissue 
on selective nutrient culture media enriched with arginine 
or urea, respectively. Media also contained a colorimetric 
indicator of mycoplasma growth. Seeding was performed 
using standard microbiological techniques as described in 
[19] with cultivation under anaerobic conditions at 370C 
with an abundance of CO2. 
detection of anti-M. hominis IgG in blood serum 
from patients
An enzyme-linked immunosorbent assay (ELISA) 
was used to detect IgG antibodies specific for M. hominis 
in patient sera (“Vector Best,” Russia), according to the 
manufacturer’s instructions. 
statistics
Reliability  of  the  correlations  among  the  groups 
under study was determined using χ² criterion (for 2-by-
2  tables  with  Fisher’s  exact  test).  Credibility  towards 
the mean age difference was determined using Student’s 
criterion. 
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